Meaghan McGeary, PhD
@mk-mcg5.bsky.social
NCI K00 Postdoc @ Jacks Lab at MIT
Yale 2022 | Holy Cross 2016
"You sort of start thinking anything's possible if you've got enough nerve."
Yale 2022 | Holy Cross 2016
"You sort of start thinking anything's possible if you've got enough nerve."
That’s a wrap for the day on antibody drug conjugates at the @mitkochinstitute.bsky.social ! Awesome course on these complicated and exciting molecules (and their relatives)! Lots more exciting anti-cancer science to come 💊 #KIsymposium
June 27, 2025 at 8:32 PM
That’s a wrap for the day on antibody drug conjugates at the @mitkochinstitute.bsky.social ! Awesome course on these complicated and exciting molecules (and their relatives)! Lots more exciting anti-cancer science to come 💊 #KIsymposium
Michael Seganish closes out the day discussing what happens when an ADC payloads detaches, even when it’s supposed to, and gets into circulation instead of into its target cell. Spoiler alert: toxic side effects @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 8:10 PM
Michael Seganish closes out the day discussing what happens when an ADC payloads detaches, even when it’s supposed to, and gets into circulation instead of into its target cell. Spoiler alert: toxic side effects @mitkochinstitute.bsky.social #KIsymposium
Puja Sapra brings perspective on the evolution of the ADC field: much learned and much to be done in terms of improving targets, understanding why different ADCs work differently, and deriving novel combos for future use. @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 7:49 PM
Puja Sapra brings perspective on the evolution of the ADC field: much learned and much to be done in terms of improving targets, understanding why different ADCs work differently, and deriving novel combos for future use. @mitkochinstitute.bsky.social #KIsymposium
Greg Thurber starts session 3 with perspective on the trajectory of ADCs in the clinic & in research- there's been a steady increase in approved ADC molecules for clinical use since early 2000s! @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 7:33 PM
Greg Thurber starts session 3 with perspective on the trajectory of ADCs in the clinic & in research- there's been a steady increase in approved ADC molecules for clinical use since early 2000s! @mitkochinstitute.bsky.social #KIsymposium
Daša Lipovšek expanding today's discussion to include miniprotein radioconjugates, which link target-binding proteins with radioisotopes that can kill cells or be detected with imaging devices. This facilitates greater targeting and functionality. @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 6:45 PM
Daša Lipovšek expanding today's discussion to include miniprotein radioconjugates, which link target-binding proteins with radioisotopes that can kill cells or be detected with imaging devices. This facilitates greater targeting and functionality. @mitkochinstitute.bsky.social #KIsymposium
Jeremiah Johnson's antibody-bottlebrush conjugates aim to enable loading more drug onto ADCs using hydrophilic sidechain linkers that stabilize more, larger, & combos of payloads. This opens doors to more options for ADC design across more contexts @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 6:30 PM
Jeremiah Johnson's antibody-bottlebrush conjugates aim to enable loading more drug onto ADCs using hydrophilic sidechain linkers that stabilize more, larger, & combos of payloads. This opens doors to more options for ADC design across more contexts @mitkochinstitute.bsky.social #KIsymposium
Dane Wittrup's lab is innovating ADCs by designing linker-less ADCs, which can enable release of payloads that cells can then take up over time- enabling better and potentially more potent targeting @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 6:18 PM
Dane Wittrup's lab is innovating ADCs by designing linker-less ADCs, which can enable release of payloads that cells can then take up over time- enabling better and potentially more potent targeting @mitkochinstitute.bsky.social #KIsymposium
Kicking off session 2 is Laurie Boyer, discussing how to visualize how molecules (like ADCs) are traveling into and around cells. Regular light microscopy isn't sufficient and more complicated super-resolution microscopes are expensive and hard to use.
June 27, 2025 at 6:02 PM
Kicking off session 2 is Laurie Boyer, discussing how to visualize how molecules (like ADCs) are traveling into and around cells. Regular light microscopy isn't sufficient and more complicated super-resolution microscopes are expensive and hard to use.
Last in Session 1: Timothy Lowinger discusses targeting immune pathways! STING agonism activates innate immunity, but it's important and difficult to deliver this only to tumor lesions. ADCs can bring the drug directly to the tumor microenvironment @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 4:17 PM
Last in Session 1: Timothy Lowinger discusses targeting immune pathways! STING agonism activates innate immunity, but it's important and difficult to deliver this only to tumor lesions. ADCs can bring the drug directly to the tumor microenvironment @mitkochinstitute.bsky.social #KIsymposium
Alison Betts: With the promise of ADCs comes a need to better understand their mechanisms + toxicities. Quantitative Systems Pharmacology modeling uses applied math to study data from ADC trials, aiding in the design of new & improved versions. @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 3:47 PM
Alison Betts: With the promise of ADCs comes a need to better understand their mechanisms + toxicities. Quantitative Systems Pharmacology modeling uses applied math to study data from ADC trials, aiding in the design of new & improved versions. @mitkochinstitute.bsky.social #KIsymposium
Next in session 1: Gerold Meinhardt with clinical data on Trastuzumab Deruxtecan, a HER2 ADC with great efficacy for breast cancer patients in a variety of contexts, including patients that have already been treated with other agents @mitkochinstitute.bsky.social #KIsymposium
June 27, 2025 at 3:20 PM
Next in session 1: Gerold Meinhardt with clinical data on Trastuzumab Deruxtecan, a HER2 ADC with great efficacy for breast cancer patients in a variety of contexts, including patients that have already been treated with other agents @mitkochinstitute.bsky.social #KIsymposium
Now, Peter Senter discussing challenges and progress in antibody drug conjugates for cancer- tricky in terms of design, potency, toxicity, etc. However, ADCs have already led to huge improvements, such as in Hodgkin's lyphoma and urothelial cancer. #KIsymposium @mitkochinstitute.bsky.social
June 27, 2025 at 2:21 PM
Now, Peter Senter discussing challenges and progress in antibody drug conjugates for cancer- tricky in terms of design, potency, toxicity, etc. However, ADCs have already led to huge improvements, such as in Hodgkin's lyphoma and urothelial cancer. #KIsymposium @mitkochinstitute.bsky.social
First, our keynote speaker @carolynbertozzi.bskyverified.social (Nobel Laureate!) introducing bioorthogonal chemistry: reactions that can occur within a living cell, with all its physiological constraints, without interfering with biology @mitkochinstitute.bsky.social #KISymposium
June 27, 2025 at 1:19 PM
First, our keynote speaker @carolynbertozzi.bskyverified.social (Nobel Laureate!) introducing bioorthogonal chemistry: reactions that can occur within a living cell, with all its physiological constraints, without interfering with biology @mitkochinstitute.bsky.social #KISymposium
Live posting today from the @mitkochinstitute.bsky.social annual symposium on Antibody Drug Conjugates #KISymposium. Excited for the amazing lineup of speakers!
June 27, 2025 at 12:54 PM
Live posting today from the @mitkochinstitute.bsky.social annual symposium on Antibody Drug Conjugates #KISymposium. Excited for the amazing lineup of speakers!
Reposted by Meaghan McGeary, PhD
We recently attended the Ludwig @mit.edu retreat and caught up with many of our colleagues there. Here, founding Director, Ludwig Professor and giant of cancer research Robert Weinberg reflects on his scientific fascinations and career.
youtu.be/UEDP2_RA6MI
#CanSky #OncoSky
youtu.be/UEDP2_RA6MI
#CanSky #OncoSky
Robert Weinberg, Ludwig MIT
YouTube video by Ludwig Cancer Research
youtu.be
June 11, 2025 at 5:55 PM
We recently attended the Ludwig @mit.edu retreat and caught up with many of our colleagues there. Here, founding Director, Ludwig Professor and giant of cancer research Robert Weinberg reflects on his scientific fascinations and career.
youtu.be/UEDP2_RA6MI
#CanSky #OncoSky
youtu.be/UEDP2_RA6MI
#CanSky #OncoSky
Reposted by Meaghan McGeary, PhD
“It’s not justifying the research—it’s justifying spending money on the research.”
This spring, Koch Institute postdoc Meaghan McGeary took that message to Capitol Hill during AACR Hill Day, urging policymakers to sustain federal funding for cancer research. buff.ly/EgnUNzq
This spring, Koch Institute postdoc Meaghan McGeary took that message to Capitol Hill during AACR Hill Day, urging policymakers to sustain federal funding for cancer research. buff.ly/EgnUNzq
June 10, 2025 at 12:40 PM
“It’s not justifying the research—it’s justifying spending money on the research.”
This spring, Koch Institute postdoc Meaghan McGeary took that message to Capitol Hill during AACR Hill Day, urging policymakers to sustain federal funding for cancer research. buff.ly/EgnUNzq
This spring, Koch Institute postdoc Meaghan McGeary took that message to Capitol Hill during AACR Hill Day, urging policymakers to sustain federal funding for cancer research. buff.ly/EgnUNzq
Reposted by Meaghan McGeary, PhD
Flybase lost all of the NIH support overnight - it is a disaster for the community. Please consider donating. I just did! www.philanthropy.cam.ac.uk/give-to-camb...
Drosophila Genetic Database
The Drosophila Genetic Database, FlyBase, is on the brink of collapse due to the sudden termination of the FlyBase NIH grant, which includes salaries for 5 literature curators based at the University ...
www.philanthropy.cam.ac.uk
June 3, 2025 at 6:23 PM
Flybase lost all of the NIH support overnight - it is a disaster for the community. Please consider donating. I just did! www.philanthropy.cam.ac.uk/give-to-camb...
Today I visited Capitol Hill with @theaacr.bsky.social and other early-career cancer researchers to advocate for increasing funding to NIH and NCI, and to share the impact of recent measures to cut federal spending on research. It was exciting and empowering, and I learned so much. 🧵
February 27, 2025 at 12:51 AM
Today I visited Capitol Hill with @theaacr.bsky.social and other early-career cancer researchers to advocate for increasing funding to NIH and NCI, and to share the impact of recent measures to cut federal spending on research. It was exciting and empowering, and I learned so much. 🧵
Last meeting- grateful for the time in @nadler.house.gov office to discuss what loss of cancer research funding means for NYC and the country @aacr_cancerresearch #FundNIH #AACRontheHill
February 26, 2025 at 9:58 PM
Last meeting- grateful for the time in @nadler.house.gov office to discuss what loss of cancer research funding means for NYC and the country @aacr_cancerresearch #FundNIH #AACRontheHill
Thanks to @whipkclark.bsky.social office for meeting with us to hear how NIH funding cuts hurt MA innovation + cancer researchers! #FundNIH #AACRontheHill @AACR @Pederfizzo
February 26, 2025 at 8:17 PM
Thanks to @whipkclark.bsky.social office for meeting with us to hear how NIH funding cuts hurt MA innovation + cancer researchers! #FundNIH #AACRontheHill @AACR @Pederfizzo
Grateful to @SenSchumer office for hearing our concerns about loss of funding for cancer research #FundNIH @theaacr.bsky.social
February 26, 2025 at 7:02 PM
Grateful to @SenSchumer office for hearing our concerns about loss of funding for cancer research #FundNIH @theaacr.bsky.social
Thanks to @edmarkey.bsky.social office for our great #AACRonthehill meeting! We are grateful for your support of cancer research funding and look forward to helping support your fight to #fundNIH @pederfizzo.bsky.social
February 26, 2025 at 5:03 PM
Thanks to @edmarkey.bsky.social office for our great #AACRonthehill meeting! We are grateful for your support of cancer research funding and look forward to helping support your fight to #fundNIH @pederfizzo.bsky.social
Beyond excited to be at Capitol Hill today with @theaacr.bsky.social at Early Career Hill Day, advocating for funding and support for cancer research #fundNIH #AACRonthehill
February 26, 2025 at 2:41 PM
Beyond excited to be at Capitol Hill today with @theaacr.bsky.social at Early Career Hill Day, advocating for funding and support for cancer research #fundNIH #AACRonthehill
We are hiring technicians! The Jacks Lab is a fun, exciting, and supportive place to learn and grow as a scientist- come study cancer with us! 🧬🐭 Apply here: careers.peopleclick.com/careerscp/cl...
Technical Associate I, Jacks Lab
MIT - Technical Associate I, Jacks Lab - Cambridge MA 02139
careers.peopleclick.com
February 5, 2025 at 7:30 PM
We are hiring technicians! The Jacks Lab is a fun, exciting, and supportive place to learn and grow as a scientist- come study cancer with us! 🧬🐭 Apply here: careers.peopleclick.com/careerscp/cl...
Thrilled to finally see my PhD work from the Bosenberg Lab published in this month's issue of #CancerImmunologyResearch !! 1/n
aacrjournals.org/cancerimmuno...
aacrjournals.org/cancerimmuno...
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Setdb1 suppresses tumor immunogenicity by repressing the expression of immunogenic genomic elements that can serve as tumor antigens and trigger an intracellular interferon loop. This work demonstrate...
aacrjournals.org
February 4, 2025 at 7:47 PM
Thrilled to finally see my PhD work from the Bosenberg Lab published in this month's issue of #CancerImmunologyResearch !! 1/n
aacrjournals.org/cancerimmuno...
aacrjournals.org/cancerimmuno...